Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2005.02.050 on December 21 2004

Journal of Clinical Oncology, Vol 23, No 4 (February 1), 2005: pp. 676-684
© 2005 American Society of Clinical Oncology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by O'Connor, O. A.
Right arrow Articles by Zelenetz, A. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O'Connor, O. A.
Right arrow Articles by Zelenetz, A. D.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Cancer Chemotherapy
Related Articles
Right arrowRelated Editorial
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

Owen A. O'Connor, John Wright, Craig Moskowitz, Jamie Muzzy, Barbara MacGregor-Cortelli, Michael Stubblefield, David Straus, Carol Portlock, Paul Hamlin, Elizabeth Choi, Otila Dumetrescu, Dixie Esseltine, Elizabeth Trehu, Julian Adams, David Schenkein, Andrew D. Zelenetz

From the Memorial Sloan-Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, Departments of Rehabilitation Medicine and Radiology, New York, NY; Millennium Pharmaceutical, Cambridge, MA; and Drug Development Branch, National Cancer Institute, Bethesda, MD

Address reprint requests to Owen A. O'Connor, MD, PhD, Memorial Sloan-Kettering Cancer Center, Department of Medicine, Box 329, Lymphoma and Developmental Chemotherapy Services, 1275 York Ave, New York, NY 10021; e-mail: oconnoro{at}mskcc.org

PURPOSE: To determine the antitumor activity of the novel proteasome inhibitor bortezomib in patients with indolent and mantle-cell lymphoma (MCL).

PATIENTS AND METHODS: Patients with indolent and MCL were eligible. Bortezomib was given at a dose of 1.5 mg/m2 on days 1, 4, 8, and 11. Patients were required to have received no more than three prior chemotherapy regimens, with at least 1 month since the prior treatment, 3 months from prior rituximab, and 7 days from prior corticosteroids; absolute neutrophil count more than 1,500/µL (500/µL if documented bone marrow involvement); and platelet count more than 50,000/µL.

RESULTS: Twenty-six patients were registered, of whom 24 were assessable. Ten patients had follicular lymphoma, 11 had MCL, three had small lymphocytic lymphoma (SLL) or chronic lymphocytic leukemia (CLL), and two had marginal zone lymphoma. The overall response rate was 58%, with one complete remission (CR), one unconfirmed CR (CRu), and four partial remissions (PR) among patients with follicular non-Hodgkin's lymphoma (NHL). All responses were durable, lasting from 3 to 24+ months. One patient with MCL achieved a CRu, four achieved a PR, and four had stable disease. One patient with MCL maintained his remission for 19 months. Both patients with marginal zone lymphoma achieved PR lasting 8+ and 11+ months, respectively. Patients with SLL or CLL have yet to respond. Overall, the drug was well tolerated, with only one grade 4 toxicity (hyponatremia). The most common grade 3 toxicities were lymphopenia (n = 14) and thrombocytopenia (n = 7).

CONCLUSION: These data suggest that bortezomib was well tolerated and has significant single-agent activity in patients with certain subtypes of NHL.

Supported under an NCI Phase II grant (UO1 CA 69913). O.A.O. is the recipient of the Leukemia and Lymphoma Society Scholar in Research Award and is supported generously by the Werner and Elaine Dannheisser Fund for Research on the Biology of Aging of the Lymphoma Foundation.

O.A.O. is on the Speakers Bureau for Millenium Pharmaceuticals.

Authors' disclosures of potential conflicts of interest are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Editorial

  • Mantle Cell Lymphoma: At Last, Some Hope for Successful Innovative Treatment Strategies
    Richard I. Fisher
    JCO 2005 23: 657-658 [Full Text]


This article has been cited by other articles:


Home page
 JCOHome page
S. de Vos, A. Goy, S. R. Dakhil, M. N. Saleh, P. McLaughlin, R. Belt, C. R. Flowers, M. Knapp, L. Hart, D. Patel-Donnelly, et al.
Multicenter Randomized Phase II Study of Weekly or Twice-Weekly Bortezomib Plus Rituximab in Patients With Relapsed or Refractory Follicular or Marginal-Zone B-Cell Lymphoma
J. Clin. Oncol., October 20, 2009; 27(30): 5023 - 5030.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
S. LUST, B. VANHOECKE, M. VAN GELE, J. BOELENS, H. VAN MELCKEBEKE, M. KAILEH, W. VANDEN BERGHE, G. HAEGEMAN, J. PHILIPPE, M. BRACKE, et al.
Xanthohumol Activates the Proapoptotic Arm of the Unfolded Protein Response in Chronic Lymphocytic Leukemia
Anticancer Res, October 1, 2009; 29(10): 3797 - 3805.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. P. Treon, L. Ioakimidis, J. D. Soumerai, C. J. Patterson, P. Sheehy, M. Nelson, M. Willen, J. Matous, J. Mattern II, J. G. Diener, et al.
Primary Therapy of Waldenstrom Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180
J. Clin. Oncol., August 10, 2009; 27(23): 3830 - 3835.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
S. A.J. VAZIRI, D. R. GRABOWSKI, J. HILL, L. R. RYBICKI, R. BURK, R. M. BUKOWSKI, M. K. GANAPATHI, and R. GANAPATHI
Inhibition of Proteasome Activity by Bortezomib in Renal Cancer Cells Is p53 Dependent and VHL Independent
Anticancer Res, August 1, 2009; 29(8): 2961 - 2969.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. J. Kuhn, S. A. Hunsucker, Q. Chen, P. M. Voorhees, M. Orlowski, and R. Z. Orlowski
Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors
Blood, May 7, 2009; 113(19): 4667 - 4676.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Delmonte, M. Ghielmini, and C. Sessa
Beyond Monoclonal Antibodies: New Therapeutic Agents in Non-Hodgkin's Lymphomas
Oncologist, May 1, 2009; 14(5): 511 - 525.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Goy, S. H. Bernstein, B. S. Kahl, B. Djulbegovic, M. J. Robertson, S. de Vos, E. Epner, A. Krishnan, J. P. Leonard, S. Lonial, et al.
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
Ann. Onc., March 1, 2009; 20(3): 520 - 525.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Ruan, K. Hajjar, S. Rafii, and J. P. Leonard
Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma
Ann. Onc., March 1, 2009; 20(3): 413 - 424.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Tabe, D. Sebasigari, L. Jin, M. Rudelius, T. Davies-Hill, K. Miyake, T. Miida, S. Pittaluga, and M. Raffeld
MDM2 Antagonist Nutlin-3 Displays Antiproliferative and Proapoptotic Activity in Mantle Cell Lymphoma
Clin. Cancer Res., February 1, 2009; 15(3): 933 - 942.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Lee, C. Suh, H. J. Kang, B.-Y. Ryoo, J. Huh, Y. H. Ko, H.-S. Eom, K. Kim, K. Park, and W. S. Kim
Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma
Ann. Onc., December 1, 2008; 19(12): 2079 - 2083.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. Paoluzzi, M. Gonen, G. Bhagat, R. R. Furman, J. R. Gardner, L. Scotto, V. D. Gueorguiev, M. L. Heaney, K. Manova, and O. A. O'Connor
The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies
Blood, October 1, 2008; 112(7): 2906 - 2916.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. J. Jones, Q. Chen, P. M. Voorhees, K. H. Young, N. Bruey-Sedano, D. Yang, and R. Z. Orlowski
Inhibition of the p53 E3 Ligase HDM-2 Induces Apoptosis and DNA Damage-Independent p53 Phosphorylation in Mantle Cell Lymphoma
Clin. Cancer Res., September 1, 2008; 14(17): 5416 - 5425.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Michopoulos, K. Petraki, C. Matsouka, E. Kastritis, H. Chrysanthopoulou, and M. A. Dimopoulos
Mantle-Cell Lymphoma (Multiple Lymphomatous Polyposis) of the Entire GI Tract
J. Clin. Oncol., March 20, 2008; 26(9): 1555 - 1557.
[Full Text] [PDF]

Home page
 JCOHome page
A. A. Chanan-Khan and B. D. Cheson
Lenalidomide for the Treatment of B-Cell Malignancies
J. Clin. Oncol., March 20, 2008; 26(9): 1544 - 1552.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Z. Orlowski and D. J. Kuhn
Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade
Clin. Cancer Res., March 15, 2008; 14(6): 1649 - 1657.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Ortega-Paino, J. Fransson, S. Ek, and C. A. K. Borrebaeck
Functionally associated targets in mantle cell lymphoma as defined by DNA microarrays and RNA interference
Blood, February 1, 2008; 111(3): 1617 - 1624.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. Chauhan, A. Singh, M. Brahmandam, K. Podar, T. Hideshima, P. Richardson, N. Munshi, M. A. Palladino, and K. C. Anderson
Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma
Blood, February 1, 2008; 111(3): 1654 - 1664.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Dai, S. Chen, L. B. Kramer, V. L. Funk, P. Dent, and S. Grant
Interactions between Bortezomib and Romidepsin and Belinostat in Chronic Lymphocytic Leukemia Cells
Clin. Cancer Res., January 15, 2008; 14(2): 549 - 558.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. J. Kuhn, Q. Chen, P. M. Voorhees, J. S. Strader, K. D. Shenk, C. M. Sun, S. D. Demo, M. K. Bennett, F. W. B. van Leeuwen, A. A. Chanan-Khan, et al.
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma
Blood, November 1, 2007; 110(9): 3281 - 3290.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
G. Cavaletti and E. Nobile-Orazio
Bortezomib-induced peripheral neurotoxicity: still far from a painless gain
Haematologica, October 1, 2007; 92(10): 1308 - 1310.
[Full Text] [PDF]

Home page
 JCOHome page
P. L. Zinzani, G. Musuraca, M. Tani, V. Stefoni, E. Marchi, M. Fina, C. Pellegrini, L. Alinari, E. Derenzini, A. de Vivo, et al.
Phase II Trial of Proteasome Inhibitor Bortezomib in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
J. Clin. Oncol., September 20, 2007; 25(27): 4293 - 4297.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. C. Kane, R. Dagher, A. Farrell, C.-W. Ko, R. Sridhara, R. Justice, and R. Pazdur
Bortezomib for the Treatment of Mantle Cell Lymphoma
Clin. Cancer Res., September 15, 2007; 13(18): 5291 - 5294.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. D. Demo, C. J. Kirk, M. A. Aujay, T. J. Buchholz, M. Dajee, M. N. Ho, J. Jiang, G. J. Laidig, E. R. Lewis, F. Parlati, et al.
Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
Cancer Res., July 1, 2007; 67(13): 6383 - 6391.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. P. Treon, Z. R. Hunter, J. Matous, R. M. Joyce, B. Mannion, R. Advani, D. Cook, J. Songer, J. Hill, B. R. Kaden, et al.
Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Results of WMCTG Trial 03-248
Clin. Cancer Res., June 1, 2007; 13(11): 3320 - 3325.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Perez-Galan, G. Roue, N. Villamor, E. Campo, and D. Colomer
The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak
Blood, May 15, 2007; 109(10): 4441 - 4449.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. I. Chen, C. T. Kouroukis, D. White, M. Voralia, E. Stadtmauer, A. K. Stewart, J. J. Wright, J. Powers, W. Walsh, and E. Eisenhauer
Bortezomib Is Active in Patients With Untreated or Relapsed Waldenstrom's Macroglobulinemia: A Phase II Study of the National Cancer Institute of Canada Clinical Trials Group
J. Clin. Oncol., April 20, 2007; 25(12): 1570 - 1575.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. J. Strauss, K. Higginbottom, S. Juliger, L. Maharaj, P. Allen, D. Schenkein, T. A. Lister, and S. P. Joel
The Proteasome Inhibitor Bortezomib Acts Independently of p53 and Induces Cell Death via Apoptosis and Mitotic Catastrophe in B-Cell Lymphoma Cell Lines
Cancer Res., March 15, 2007; 67(6): 2783 - 2790.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. M. Horton, D. Pati, S. E. Plon, P. A. Thompson, L. R. Bomgaars, P. C. Adamson, A. M. Ingle, J. Wright, A. H. Brockman, M. Paton, et al.
A Phase 1 Study of the Proteasome Inhibitor Bortezomib in Pediatric Patients with Refractory Leukemia: a Children's Oncology Group Study
Clin. Cancer Res., March 1, 2007; 13(5): 1516 - 1522.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J.-P. Armand, A. K. Burnett, J. Drach, J.-L. Harousseau, B. Lowenberg, and J. San Miguel
The Emerging Role of Targeted Therapy for Hematologic Malignancies: Update on Bortezomib and Tipifarnib
Oncologist, March 1, 2007; 12(3): 281 - 290.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Van Waes
Nuclear Factor-{kappa}B in Development, Prevention, and Therapy of Cancer
Clin. Cancer Res., February 15, 2007; 13(4): 1076 - 1082.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. R. Jazirehi, M. I. Vega, and B. Bonavida
Development of Rituximab-Resistant Lymphoma Clones with Altered Cell Signaling and Cross-Resistance to Chemotherapy
Cancer Res., February 1, 2007; 67(3): 1270 - 1281.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
F Morschhauser, S Depil, E Jourdan, M Wetterwald, R Bouabdallah, G Marit, P Solal-Celigny, C Sebban, B Coiffier, N Chouaki, et al.
Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma
Ann. Onc., February 1, 2007; 18(2): 370 - 375.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Duan, J. Friedman, L. Nottingham, Z. Chen, G. Ara, and C. Van Waes
Nuclear factor-{kappa}B p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101
Mol. Cancer Ther., January 1, 2007; 6(1): 37 - 50.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
E. Reinstein and A. Ciechanover
Narrative review: protein degradation and human diseases: the ubiquitin connection.
Ann Intern Med, November 7, 2006; 145(9): 676 - 684.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. P. Fanucchi, F. V. Fossella, R. Belt, R. Natale, P. Fidias, D. P. Carbone, R. Govindan, L. E. Raez, F. Robert, M. Ribeiro, et al.
Randomized Phase II Study of Bortezomib Alone and Bortezomib in Combination With Docetaxel in Previously Treated Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., November 1, 2006; 24(31): 5025 - 5033.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C. R. Chitambar, J. P. Wereley, and S. Matsuyama
Gallium-induced cell death in lymphoma: role of transferrin receptor cycling, involvement of Bax and the mitochondria, and effects of proteasome inhibition.
Mol. Cancer Ther., November 1, 2006; 5(11): 2834 - 2843.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. I. Fisher, S. H. Bernstein, B. S. Kahl, B. Djulbegovic, M. J. Robertson, S. de Vos, E. Epner, A. Krishnan, J. P. Leonard, S. Lonial, et al.
Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
J. Clin. Oncol., October 20, 2006; 24(30): 4867 - 4874.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
Y. Ishii, A. Pirkmaier, J. V. Alvarez, D. A. Frank, I. Keselman, D. Logothetis, J. Mandeli, M. J. O'Connell, S. Waxman, and D. Germain
Cyclin d1 overexpression and response to bortezomib treatment in a breast cancer model.
J Natl Cancer Inst, September 6, 2006; 98(17): 1238 - 1247.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C. Yu, B. B. Friday, J.-P. Lai, L. Yang, J. Sarkaria, N. E. Kay, C. A. Carter, L. R. Roberts, S. H. Kaufmann, and A. A. Adjei
Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
Mol. Cancer Ther., September 1, 2006; 5(9): 2378 - 2387.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B. Kahl, W. Longo, J. Eickhoff, J Zehnder, C Jones, J Blank, T McFarland, W Bottner, H Rezazedeh, J Werndli, et al.
Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network
Ann. Onc., September 1, 2006; 17(9): 1418 - 1423.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Nencioni, K. Schwarzenberg, K. M. Brauer, S. M. Schmidt, A. Ballestrero, F. Grunebach, and P. Brossart
Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation
Blood, July 15, 2006; 108(2): 551 - 558.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Ruiz, Y. Krupnik, M. Keating, J. Chandra, M. Palladino, and D. McConkey
The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia.
Mol. Cancer Ther., July 1, 2006; 5(7): 1836 - 1843.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. D. Cheson and G. P. Canellos
The cancer and leukemia group B lymphoma committee.
Clin. Cancer Res., June 1, 2006; 12(11): 3572s - 3575s.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. J. Strauss, L. Maharaj, S. Hoare, P. W. Johnson, J. A. Radford, S. Vinnecombe, L. Millard, A. Rohatiner, A. Boral, E. Trehu, et al.
Bortezomib Therapy in Patients With Relapsed or Refractory Lymphoma: Potential Correlation of In Vitro Sensitivity and Tumor Necrosis Factor Alpha Response With Clinical Activity
J. Clin. Oncol., May 1, 2006; 24(13): 2105 - 2112.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
O. A. O'Connor, E. A. Smith, L. E. Toner, J. Teruya-Feldstein, S. Frankel, M. Rolfe, X. Wei, S. Liu, G. Marcucci, K. K. Chan, et al.
The Combination of the Proteasome Inhibitor Bortezomib and the Bcl-2 Antisense Molecule Oblimersen Sensitizes Human B-Cell Lymphomas to Cyclophosphamide.
Clin. Cancer Res., May 1, 2006; 12(9): 2902 - 2911.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
L. Arcaini, S. Burcheri, A. Rossi, F. Passamonti, M. Paulli, E. Boveri, E. Brusamolino, E. Orlandi, A. Molteni, A. Pulsoni, et al.
Nongastric Marginal-Zone B-Cell MALT Lymphoma: Prognostic Value of Disease Dissemination.
Oncologist, March 1, 2006; 11(3): 285 - 291.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Younes, B. Pro, and L. Fayad
Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma
Blood, February 15, 2006; 107(4): 1731a - 1732.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
E. J. Hoorn, J. Lindemans, and R. Zietse
Development of severe hyponatraemia in hospitalized patients: treatment-related risk factors and inadequate management
Nephrol. Dial. Transplant., January 1, 2006; 21(1): 70 - 76.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. S. Herbst, D. F. Bajorin, H. Bleiberg, D. Blum, D. Hao, B. E. Johnson, R. F. Ozols, G. D. Demetri, P. A. Ganz, M. G. Kris, et al.
Clinical Cancer Advances 2005: Major Research Advances in Cancer Treatment, Prevention, and Screening--A Report From the American Society of Clinical Oncology
J. Clin. Oncol., January 1, 2006; 24(1): 190 - 205.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Perez-Galan, G. Roue, N. Villamor, E. Montserrat, E. Campo, and D. Colomer
The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status
Blood, January 1, 2006; 107(1): 257 - 264.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. E. Witzig
Current Treatment Approaches for Mantle-Cell Lymphoma
J. Clin. Oncol., September 10, 2005; 23(26): 6409 - 6414.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
O. A. O'Connor
Targeting Histones and Proteasomes: New Strategies for the Treatment of Lymphoma
J. Clin. Oncol., September 10, 2005; 23(26): 6429 - 6436.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. Boll, H. Hansen, F. Heuck, K. Reiners, P. Borchmann, A. Rothe, A. Engert, and E. Pogge von Strandmann
The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis
Blood, September 1, 2005; 106(5): 1839 - 1842.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. E. Witzig, S. M. Geyer, I. Ghobrial, D. J. Inwards, R. Fonseca, P. Kurtin, S. M. Ansell, R. Luyun, P. J. Flynn, R. F. Morton, et al.
Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma
J. Clin. Oncol., August 10, 2005; 23(23): 5347 - 5356.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Nencioni, L. Wille, G. Dal Bello, D. Boy, G. Cirmena, S. Wesselborg, C. Belka, P. Brossart, F. Patrone, and A. Ballestrero
Cooperative Cytotoxicity of Proteasome Inhibitors and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Chemoresistant Bcl-2-Overexpressing Cells
Clin. Cancer Res., June 1, 2005; 11(11): 4259 - 4265.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. I. Fisher
Mantle Cell Lymphoma: At Last, Some Hope for Successful Innovative Treatment Strategies
J. Clin. Oncol., February 1, 2005; 23(4): 657 - 658.
[Full Text] [PDF]

Home page
 ASH Education BookHome page
R. Z. Orlowski
The Ubiquitin Proteasome Pathway from Bench to Bedside
Hematology, January 1, 2005; 2005(1): 220 - 225.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2005 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online